We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Seizure Prophylaxis in Aneurysm Repair (SPAR)

This study is currently recruiting participants.
Verified May 2017 by Aditya S. Pandey, MD, University of Michigan
ClinicalTrials.gov Identifier:
First Posted: February 28, 2013
Last Update Posted: May 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Aditya S. Pandey, MD, University of Michigan
After a thorough review of the existing literature as well as a review of our own practice, the investigators have concluded that the decision to treat patients undergoing aneurysm repair with levetiracetam has reached true clinical equipoise. In other words, the investigators cannot favor a decision to either administer or not administer this drug in these patients based on the existing information. The utility of anti-epileptic prophlaxis in the perioperative period for patients undergoing intracranial aneurysm repair remains a common practice that is not supported by the current literature that includes retrospective analyses as well as prospective trials for similar but not identical types of patients. The investigators propose to settle this dilemma by performing a prospective randomized trial in patients undergoing aneurysm repair in order to definitively determine if the common practice of perioperative antiepileptic drug administration has any utility.

Condition Intervention Phase
Intracranial Aneurysms Seizure Drug: Levetiracetam Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Seizure Prophylaxis in Aneurysm Repair

Resource links provided by NLM:

Further study details as provided by Aditya S. Pandey, MD, University of Michigan:

Primary Outcome Measures:
  • Incidence of seizure [ Time Frame: 1 year from procedure ]

Estimated Enrollment: 400
Study Start Date: February 2013
Estimated Study Completion Date: February 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Levetiracetam
500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days.
Drug: Levetiracetam
Details covered in Arm Descriptions.
Other Name: Keppra
No Intervention: No levetiracetam
No levetiracetam


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult (≥18 years)
  • Presence of intracranial aneurysm (with or without rupture)
  • Treating surgeon has recommended surgical repair of the aneurysm

Exclusion Criteria:

  • History of seizures within last 10 years
  • History of epilepsy
  • History of prior stroke
  • Currently prescribed medication with anti-epileptic activity (keppra, dilantin, tegretol, lamictal, topamax, etc.)
  • Brain tumor
  • Pregnant or nursing woman
  • Known levetiracetam allergy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01801072

Contact: Aditya Pandey, MD 734-615-4486 adityap@med.umich.edu
Contact: Ron Ball 734-647-5436 rmball@med.umich.edu

United States, Michigan
University of Michigan Health System Recruiting
Ann Arbor, Michigan, United States, 48109
Principal Investigator: Aditya Pandey, MD         
Sub-Investigator: Wajd Al-Holou, MD         
Sub-Investigator: Cormac Maher, MD         
Sub-Investigator: Christopher Roark, MD         
Sub-Investigator: William Stetler Jr, MD         
Sub-Investigator: Jennifer Strahle, MD         
Sub-Investigator: Byron Thompson, MD         
Sub-Investigator: TJ Wilson, MD         
Sponsors and Collaborators
University of Michigan
Principal Investigator: Aditya S Pandey, MD University of Michigan
  More Information

Responsible Party: Aditya S. Pandey, MD, Assistant Professor of Neurosurgery and Assistant Professor of Radiology, Medical School, University of Michigan
ClinicalTrials.gov Identifier: NCT01801072     History of Changes
Other Study ID Numbers: HUM00064523
First Submitted: February 26, 2013
First Posted: February 28, 2013
Last Update Posted: May 18, 2017
Last Verified: May 2017

Additional relevant MeSH terms:
Intracranial Aneurysm
Vascular Diseases
Cardiovascular Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Intracranial Arterial Diseases
Cerebrovascular Disorders
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs